Capital Group Private Client Services’s Gilead Sciences GILD Stock Holding History

Capital Group Private Client Services’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-13,643	Closed	-$1.05M	–	240
2023 Q2	$1.05M	Sell	13,643 -202	-1%	-$16.1K	0.01%	198
2023 Q1	$1.15M	Buy	13,845 +14	+0.1%	+$1.16K	0.01%	195
2022 Q4	$1.19M	Sell	13,831 -768	-5%	-$60.8K	0.02%	190
2022 Q3	$901K	Sell	14,599 -81	-0.6%	-$5.11K	0.01%	194
2022 Q2	$907K	Sell	14,680 -43,305	-75%	-$2.68M	0.01%	194
2022 Q1	$3.45M	Sell	57,985 -770,325	-93%	-$49.2M	0.04%	175
2021 Q4	$60.1M	Sell	828,310 -46,450	-5%	-$3.2M	0.64%	52
2021 Q3	$61.1M	Buy	+874,760	New	+$61.5M	0.71%	47

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Group Private Client Services's GILD Position: Q3 2023 in Review

Capital Group Private Client Services sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 13,643 shares — an estimated $1.05M sold.

Capital Group Private Client Services first reported a position in GILD in Q3 2021 and held it in 8 quarters. The position peaked at $61.1M in Q3 2021. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.

Capital Group Private Client Services reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
Capital Group Private Client Services sold 13,643 Gilead Sciences shares in Q3 2023, an estimated $1.05M.
Capital Group Private Client Services first reported a position in Gilead Sciences in Q3 2021 and held it in 8 quarters.
Capital Group Private Client Services's Gilead Sciences position peaked at $61.1M in Q3 2021.
1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.

Based on Capital Group Private Client Services's 13F filing for Q3 2023, filed 13 Nov 2023.